Investor Relations

(Security Code :4506 TSE Prime)

Pick Up

Oct. 01, 2025	Academic Conference Presentation on the Results of Phase 1 Clinical Study in Europe on a Novel Universal Influenza Vaccine Candidate Formulated with Sumitomo Pharma’s Proprietary TLR7 Adjuvant (DSP-0546)	R&D
Sep. 02, 2025	Sumitomo Pharma Announces Organizational Realignments and Personnel Changes	Corporate
Aug. 29, 2025	Sumitomo Pharma Selected for Five Inclusions as a Constituent of GPIF-Adopted ESG Indexes	Sustainability
Aug. 07, 2025	Posted Conference on Q1 FY2025 Financial Results [Webcast]	Finances
Aug. 05, 2025	Announcement on the Submission of the Application of Manufacturing and Marketing Authorization for Allogeneic iPS Cell-Derived dopaminergic neural progenitor cells in Japan	R&D
Aug. 05, 2025	Notice Regarding the Completion of the CRAFT Regenerative Medicine and Cell Therapy Manufacturing Facility	Corporate

Oct. 31, 2025	2nd Quarter of FY2025 financial results announcement, conference on 2nd quarter FY2025 financial results for Analysts, Investors, and the Press (planned, 3:30 p.m.)